Shopping Cart
Remove All
Your shopping cart is currently empty
Olendalizumab (Synonyms: Lendalizumab, ALXN1007)
Catalog No. T77107 Copy Product Info
🥰Excellent
Olendalizumab (ALXN-1007) is a humanized monoclonal antibody specifically targeting the complement component C5a. The compound binds to C5a, blocking its interaction with the C5aR (CD88) receptor, thereby inhibiting C5a-mediated inflammatory responses, neutrophil chemotaxis, and activation. In clinical and experimental research, Olendalizumab is investigated for treating complement-mediated disorders, such as sepsis, graft-versus-host disease (GVHD), and severe pneumonia or cytokine storms induced by viral infections (e.g., COVID-19).
Olendalizumab
Copy Product Info🥰Excellent
Catalog No. T77107
Synonyms Lendalizumab, ALXN1007
Olendalizumab (ALXN-1007) is a humanized monoclonal antibody specifically targeting the complement component C5a. The compound binds to C5a, blocking its interaction with the C5aR (CD88) receptor, thereby inhibiting C5a-mediated inflammatory responses, neutrophil chemotaxis, and activation. In clinical and experimental research, Olendalizumab is investigated for treating complement-mediated disorders, such as sepsis, graft-versus-host disease (GVHD), and severe pneumonia or cytokine storms induced by viral infections (e.g., COVID-19).
Olendalizumab
Cas No. 2210314-30-8
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 5 mg | Inquiry | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Olendalizumab (ALXN-1007) is a humanized monoclonal antibody specifically targeting the complement component C5a. The compound binds to C5a, blocking its interaction with the C5aR (CD88) receptor, thereby inhibiting C5a-mediated inflammatory responses, neutrophil chemotaxis, and activation. In clinical and experimental research, Olendalizumab is investigated for treating complement-mediated disorders, such as sepsis, graft-versus-host disease (GVHD), and severe pneumonia or cytokine storms induced by viral infections (e.g., COVID-19). |
| In vitro | In a Gyrolab assay, Olendalizumab demonstrated high specificity as a biotinylated capture reagent (working concentration: 100 µg/mL in Bioaffy wash 1), working alongside AlexaFluor-labeled anti-C5a clone 2942 (4 µg/mL in Rexxip F) to enable precise quantitation of free C5a in human plasma [1]. |
| In vivo | In viral infection models, Olendalizumab acted as a potent C5a inhibitor to mitigate lung injury mediated by complement components (C3, C5a, C5b-9) and receptors (C3aR, C5aR), specifically blocking the non-silent complement activation triggered by coronaviruses [2]. |
| Synonyms | Lendalizumab, ALXN1007 |
| Reactivity | Virus |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | ComplementproteinC5a |
| Cas No. | 2210314-30-8 |
| Isotype | IgG2SA |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Olendalizumab | purchase Olendalizumab | Olendalizumab cost | order Olendalizumab | Olendalizumab in vivo | Olendalizumab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.